Bayer: Science For A Better Life

United States of America

Oncology Information for Grant Submissions

Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Pancreatic Cancer

Intended Audience: Oncologists, Pathologists, Surgeons, Community HCPs, Patients/Caregivers

Areas of interest based on referenced literature:

  • Treatment and management of Pancreatic Cancer
  • Education on biomarker driven testing strategies/appropriate testing modalities
  • Role of NTRK gene fusion and impact of TRK gene fusion/TRK testing in treatment algorithms for Pancreatic Cancer
  • Understanding of efficacy and safety profiles of approved TRK inhibitors in Pancreatic Cancer
  • Multi-disciplinary approach to precision medicine
  • Understanding and management of adverse event profiles

Proposal Requirements

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning objectives
  • Proposed faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan (required on a quarterly basis)
  • Detailed budget

Provider Justification:

  • Copy of most recent accreditation letter and status
  • Sample of other program(s) in similar therapeutic area


Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability


  • Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
  • Hong, D et al. Long-term efficacy and safety of Larotrectinib in an integrated database of patients with TRK fusion cancer. ASCO 2021 presentation.
  • Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (link)
  • National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hepatobiliary
  • Boni, V et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset. WCGI 2021 Presentation.
  • Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021 Sep 17;5(1):86. doi: 10.1038/s41698-021-00222-y.